PTC Other Operating Expenses vs Tax Provision Analysis
PTCT Stock | USD 31.18 0.52 1.64% |
PTC Therapeutics financial indicator trend analysis is much more than just breaking down PTC Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PTC Therapeutics is a good investment. Please check the relationship between PTC Therapeutics Other Operating Expenses and its Tax Provision accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.
Other Operating Expenses vs Tax Provision
Other Operating Expenses vs Tax Provision Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PTC Therapeutics Other Operating Expenses account and Tax Provision. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between PTC Therapeutics' Other Operating Expenses and Tax Provision is -0.67. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Tax Provision in the same time period over historical financial statements of PTC Therapeutics, assuming nothing else is changed. The correlation between historical values of PTC Therapeutics' Other Operating Expenses and Tax Provision is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of PTC Therapeutics are associated (or correlated) with its Tax Provision. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Tax Provision has no effect on the direction of Other Operating Expenses i.e., PTC Therapeutics' Other Operating Expenses and Tax Provision go up and down completely randomly.
Correlation Coefficient | -0.67 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of PTC Therapeutics. It is also known as PTC Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Most indicators from PTC Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PTC Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.At this time, PTC Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.80 in 2024, despite the fact that Tax Provision is likely to grow to (82.7 M).
2021 | 2022 | 2023 | 2024 (projected) | Research Development | 540.7M | 651.5M | 666.6M | 699.9M | Total Revenue | 538.6M | 698.8M | 937.8M | 984.7M |
PTC Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
PTC Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PTC Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.6B | 2.2B | 1.9B | 1.7B | 1.9B | 2.0B | |
Other Current Liab | 197.3M | 245.8M | 60.8M | 365.2M | 580.3M | 609.3M | |
Total Current Liabilities | 235.9M | 277.3M | 509.3M | 406.2M | 603.1M | 633.3M | |
Total Stockholder Equity | 594.3M | 482.0M | 1.4M | (347.1M) | (818.6M) | (777.6M) | |
Other Liab | 490.7M | 1.0B | 1.1B | 269.5M | 309.9M | 263.2M | |
Accounts Payable | 10.3M | 18.7M | 23.0M | 27.3M | 6.0M | 9.9M | |
Cash | 686.6M | 208.8M | 773.4M | 410.7M | 594.0M | 623.7M | |
Other Assets | 16.4M | 60.6M | 46.5M | 33.4M | 38.4M | 40.3M | |
Long Term Debt | 293.9M | 309.1M | 281.9M | 571.7M | 1.9B | 2.0B | |
Short Term Investments | 398.5M | 894.8M | 583.7M | 130.9M | 282.7M | 281.6M | |
Other Current Assets | 17.9M | 39.5M | (126.3M) | 105.7M | 150.3M | 157.8M | |
Total Liab | 1.0B | 1.7B | 1.9B | 2.1B | 2.7B | 2.9B | |
Property Plant Equipment | 21.5M | 33.8M | 130.0M | 72.6M | 83.5M | 87.7M | |
Short Long Term Debt Total | 313.9M | 420.4M | 431.4M | 703.6M | 415.0M | 255.9M | |
Property Plant And Equipment Net | 21.5M | 118.2M | 130.0M | 175.0M | 179.0M | 187.9M | |
Current Deferred Revenue | 8.2M | 4.2M | 265.8M | 1.4M | 801K | 761.0K | |
Net Debt | (372.7M) | 211.6M | (341.9M) | 292.9M | (179.0M) | (187.9M) | |
Retained Earnings | (1.2B) | (1.6B) | (2.1B) | (2.7B) | (3.3B) | (3.1B) | |
Non Current Assets Total | 844.5M | 976.5M | 1.2B | 1.0B | 684.6M | 480.6M | |
Non Currrent Assets Other | 30.1M | 60.6M | 227.5M | 48.6M | 20.0M | 33.4M | |
Cash And Short Term Investments | 686.6M | 1.1B | 773.4M | 410.7M | 876.7M | 450.9M | |
Net Receivables | 55.5M | 69.9M | 110.5M | 155.6M | 161.0M | 169.1M | |
Common Stock Total Equity | 62K | 70K | 71K | 72K | 82.8K | 45.3K | |
Common Stock Shares Outstanding | 58.9M | 66.0M | 70.5M | 71.7M | 74.8M | 49.7M | |
Liabilities And Stockholders Equity | 1.6B | 2.2B | 1.9B | 1.7B | 1.9B | 1.0B | |
Non Current Liabilities Total | 793.6M | 1.4B | 1.2B | 1.6B | 2.1B | 2.2B | |
Other Stockholder Equity | 1.8B | 2.2B | 2.1B | 2.3B | 2.5B | 2.6B | |
Property Plant And Equipment Gross | 21.5M | 118.2M | 157.2M | 212.4M | 230.3M | 241.8M | |
Total Current Assets | 779.3M | 1.2B | 773.4M | 693.8M | 1.2B | 1.3B | |
Accumulated Other Comprehensive Income | (10.6M) | (61.0M) | (24.3M) | 4.8M | (1.3M) | (1.3M) | |
Short Term Debt | 20M | 8.7M | 159.8M | 12.4M | 16.0M | 15.2M | |
Common Stock | 62K | 70K | 71K | 72K | 75K | 48.1K | |
Net Tangible Assets | (198.5M) | (315.7M) | (805.7M) | (1.1B) | (1.0B) | (970.7M) | |
Retained Earnings Total Equity | (1.2B) | (1.6B) | (2.1B) | (2.7B) | (2.4B) | (2.3B) | |
Capital Surpluse | 1.8B | 2.2B | 2.1B | 2.3B | 2.7B | 1.6B | |
Inventory | 19.3M | 18.7M | 15.9M | 21.8M | 30.6M | 32.1M | |
Deferred Long Term Liab | 130.9M | 136.7M | 137.1M | 102.8M | 118.3M | 70.3M | |
Non Current Liabilities Other | 368.9M | 1.0B | 1.0B | 971.9M | 141K | 134.0K |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PTC Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Equity Valuation Check real value of public entities based on technical and fundamental data |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.69) | Revenue Per Share 12.281 | Quarterly Revenue Growth (0.05) | Return On Assets (0.10) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.